Improved patient and primary renal allograft survival in uremic diabetic recipients

Transplantation. 1982 Dec;34(6):319-25. doi: 10.1097/00007890-198212000-00002.

Abstract

From January 1968 to December 1981, 470 uremic diabetic patients received primary renal allografts at the University of Minnesota. Until 1979, the patient and graft survival rates were less good in diabetic than in nondiabetic recipients. Since 1979, the results in diabetics have been at least equal to those achieved in nondiabetic patients. Two-year actuarial patient and graft survival rates in diabetic renal allograft recipients were, respectively, 71 and 66% from 1968 to 1976 (n = 156), 78 and 64% from 1976 to 1979 (n = 187), and 88 and 82% from 1979 to 1981 (n = 127). Improved survival rates were seen in all donor source and recipient age categories. For comparison, the 2-year patient and graft survival rates in nondiabetic renal allograft recipients who received transplants between 1979 and 1981 (n = 162) were 92 and 79%. Changes associated with improved survival rates included performance of pretransplant splenectomy on all patients except those receiving grafts from HLA-identical siblings, deliberate transfusions of blood from greater than or equal to 5 random donors at least 1 month before transplantation, intensive insulin therapy for diabetic management post-transplant, and less vigorous treatment of repetitive rejection episodes. The current results show that diabetic recipients are no longer at higher risk than nondiabetics for graft or patient loss, at least during the first 2 years after transplantation.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aging
  • Cyclosporins / therapeutic use
  • Diabetic Nephropathies / complications
  • Diabetic Nephropathies / mortality*
  • Diabetic Nephropathies / therapy
  • Graft Survival*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kidney Transplantation* / mortality
  • Long-Term Care
  • Middle Aged
  • Risk
  • Splenectomy
  • Tissue Donors
  • Uremia / etiology
  • Uremia / mortality*
  • Uremia / therapy

Substances

  • Cyclosporins
  • Immunosuppressive Agents